News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galapagos NV (GLPG.BR) Announces GSK2586184 JAK1 Molecule Moves Into Phase 2 For Ulcerative Colitis


11/27/2013 9:27:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MECHELEN, Belgium, Nov. 27, 2013 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announced today that GlaxoSmithKline plan to initiate an exploratory Phase 2 study with GSK2586184 (formerly GLPG0778) in patients with ulcerative colitis, a third indication for this investigational molecule, in addition to psoriasis and lupus.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES